// App-Quantinova.ai

TPS5612 : Open label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study-GETHI 2013-01.

Researchers

Presenter

  • Jf. Rodriguez-Moreno

Principal Investigators

  • Jess Garca-Donas

  • Laia Garrigos

  • Zaida Garcia-Casado

  • Enrique Grande

  • Andres Redondo

  • Juan Fernando Cueva

  • Maria Jesus Rubio

  • Susana Hernando Polo

  • Isabel Bover

  • Isabel Palacio

  • Alicia Hurtado

  • Nuria Lanez

  • Ana Santaballa

Medical Centers

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • Hospital Universitario La Paz, Madrid, Spain

  • Hospital Universitario Ramon y Cajal, Medical Oncology Department, Madrid, Spain

  • Hospital Del Mar, Barcelona, Spain

  • Hospital Universitario Fundacion Alcorcon, Alcorcon, SpainComplejo Hospitalario de Navarra, Pamplona, SpainHospital Universitari i Politecnic La Fe, Valencia, Spain

  • START Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

  • Hospital Universitario Fundacion de Alcorcon, Alcorcon, Spain

  • University Hospital Reina Sofia, Cordoba, Spain

  • Hospital Central de Asturias, Oviedo, Spain

  • Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain

  • Hospital Son Llatzer, Palma De Mallorca, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Ovarian cancer

Biomarkers

  • Cytochrome P450 Family 17 subfamily A member 1

  • Forkhead Box L2

Drug/Treatment

  • aminoglutethimide

  • Enzalutamide

  • Ketoconazole

  • CB-7598

  • Orteronel

Outcome

  • N/A

Study Design

  • open label

  • single arm

Phase

  • II

Study Id's

  • NCT02101684

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved